NCT00286377

Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of Prosaptide Over 6 Weeks of Treatment for the Relief of Neuropathic Pain Associated With HIV-1

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 350 (planned)
• Sponsor: Savient Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a double-blind, placebo-controlled, parallel groups study to determine whether prosptide is effective in relieving pain in patients who have sensory neuropathic pain related to their HIV infection or the drugs used to treat it.

Detailed description

Sensory neruopathies are the most frequent neurological complicaton of HIV infection and its treatmet with antiretrovirals. To date, there are few effective treatments, and all are symptomatic treatments for pain. Management typically involves the intiation and adjustment of pain-modifying therapies, and the adjustment or discontinuation of potentially neurotoxic antiretrovirals, thereby limiting the choice of HAART regimens. In precinical animal models,prosaptide has been shown to be efficacious in the treatment of neuropathic pain caused by a variety of different mechanisms. Hypothesis: Prosaptide will improve neuropathic pain in HIV-associated sensory neuroathies,and will be safe and well tolerated in subjects. Comparisons: 4, 8, or 16 mg prosaptide vs. placebo

Conditions

• HIV
• Peripheral Nervous System Disorders

Interventions

Type	Name	Description
DRUG	prosaptide

Timeline

• Start date: 2003-09-01
• Completion: 2004-12-01
• First posted: 2006-02-03
• Last updated: 2006-02-03